Compare LQDA & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | ITGR |
|---|---|---|
| Founded | 2004 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2018 | 2000 |
| Metric | LQDA | ITGR |
|---|---|---|
| Price | $42.70 | $86.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $38.60 | ★ $86.67 |
| AVG Volume (30 Days) | ★ 2.3M | 555.5K |
| Earning Date | 03-18-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.42 |
| Revenue | $69,216,000.00 | ★ $1,831,074,000.00 |
| Revenue This Year | $993.31 | $9.58 |
| Revenue Next Year | $219.14 | N/A |
| P/E Ratio | ★ N/A | $35.53 |
| Revenue Growth | ★ 343.41 | 9.54 |
| 52 Week Low | $11.26 | $62.00 |
| 52 Week High | $46.67 | $144.76 |
| Indicator | LQDA | ITGR |
|---|---|---|
| Relative Strength Index (RSI) | 59.86 | 61.15 |
| Support Level | $41.34 | $85.11 |
| Resistance Level | $46.67 | $87.21 |
| Average True Range (ATR) | 2.51 | 1.99 |
| MACD | -0.02 | -0.40 |
| Stochastic Oscillator | 63.78 | 63.80 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.